Is Serepta Really a Biomedical Company?

Repta, a $12 billion company probably now with $2 billion in cash and cash equivalents. This is definitely a name that we've talked about. Quickly on Novavax though, which is now probably below half a billion dollars in market cap. But this was a $250 stock in I think August of 2021. We said be careful here. It shows the binary outcomes for some of these companies. On the flip side it shows the power that one drug can have for the balance sheets or another like Serepta.